Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5.6% – What’s Next?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price was up 5.6% during mid-day trading on Wednesday . The company traded as high as $70.13 and last traded at $69.96. Approximately 852,613 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 1,776,028 shares. The stock had previously closed at $66.28.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s FY2026, FY2027, and several 2027 quarterly EPS estimates, signaling improving earnings expectations for Halozyme Therapeutics (NASDAQ: HALO).
• Positive Sentiment: Higher longer-term profit forecasts, including FY2027 and FY2028, may help support Halozyme’s premium valuation if execution stays on track.
• Neutral Sentiment: Zacks also made some mixed changes, including a slight cut to Q2 2026 and Q1 2028 estimates, so the outlook is constructive but not uniformly bullish.
• Neutral Sentiment: Recent CEO share sales were disclosed, but they were executed under a pre-arranged 10b5-1 trading plan, which reduces the likelihood that investors view them as a negative signal.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HALO shares. Morgan Stanley decreased their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Stock Performance

The company has a market capitalization of $8.49 billion, a PE ratio of 25.76, a PEG ratio of 0.29 and a beta of 0.88. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a 50-day moving average price of $66.63 and a two-hundred day moving average price of $68.72.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.61 EPS for the current fiscal year.

Insider Activity

In related news, COO Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the completion of the sale, the chief operating officer owned 14,366 shares of the company’s stock, valued at approximately $974,014.80. This trade represents a 58.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $55,088,215. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 122,107 shares of company stock worth $8,254,834. 2.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC boosted its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Clearstead Advisors LLC boosted its stake in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. boosted its stake in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Finally, Penserra Capital Management LLC bought a new stake in Halozyme Therapeutics during the third quarter valued at $52,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.